FMP
Protara Therapeutics, Inc.
TARA
NASDAQ
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
2.93 USD
-0.05 (-1.71%)
About
ceo
Mr. Jesse Shefferman
sector
Healthcare
industry
Biotechnology
website
https://www.protaratx.com
exchange
NASDAQ
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
CIK
0001359931
ISIN
US74365U1079
CUSIP
74365U107
Address
345 Park Avenue South
Phone
646 844 0337
Country
US
Employee
26
IPO Date
Oct 22, 2014
Key Executives
